MIGRA THERAPEUTICS
Migra Therapeutics is developing nanotechnology therapies for cancer. Some types of cancer, particularly pancreatic cancer and breast cancer, are comprised of dense barrier cells called โstroma,โ which resist penetration by drug therapy. Migra Therapeutics has engineered a protein that targets a receptor in these cancer cells; the protein binds to the cancer cells to deliver therapies more effectively. Migraโs system can be used to deliver chemotherapy drugs, therapeutic antibodies and most importantly, nanoparticle drugs. Early testing of the companyโs targeted drug delivery system has shown promising results for treating pancreatic and breast cancer. More testing is needed, but the company aims to fundamentally change the future of nanotechnology cancer treatment.
MIGRA THERAPEUTICS
Industry:
Biotechnology Life Science Therapeutics
Status:
Active
Total Funding:
87.49 K USD
Similar Organizations
Enliven Therapeutics
Enliven Therapeutics is a precision oncology company developing small molecule therapies to extend and improve patient lives.
ParkCell
ParkCell is a development of new diagnostics and cell-based therapies for Parkinsonโs Disease.
Sophia Bioscience
Sophia Bioscience develops new pharmaceutical treatments for early and metastatic cancers.
Vaxira
Vaxira is a therapeutic vaccine for the treatment of non-small cell lung cancer
Investors List
Georgia Research Alliance
Georgia Research Alliance investment in Grant - Migra Therapeutics
Georgia Research Alliance
Georgia Research Alliance investment in Grant - Migra Therapeutics